Cargando…

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series

We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Waddington-Cruz, Márcia, Schmidt, Hartmut, Botteman, Marc F., Carter, John A., Stewart, Michelle, Hopps, Markay, Fallet, Shari, Amass, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368811/
https://www.ncbi.nlm.nih.gov/pubmed/30736835
http://dx.doi.org/10.1186/s13023-019-1000-1
_version_ 1783394069635923968
author Waddington-Cruz, Márcia
Schmidt, Hartmut
Botteman, Marc F.
Carter, John A.
Stewart, Michelle
Hopps, Markay
Fallet, Shari
Amass, Leslie
author_facet Waddington-Cruz, Márcia
Schmidt, Hartmut
Botteman, Marc F.
Carter, John A.
Stewart, Michelle
Hopps, Markay
Fallet, Shari
Amass, Leslie
author_sort Waddington-Cruz, Márcia
collection PubMed
description We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden). East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors. The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%). Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]). Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4). The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN. Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%). Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1000-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6368811
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63688112019-02-15 Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series Waddington-Cruz, Márcia Schmidt, Hartmut Botteman, Marc F. Carter, John A. Stewart, Michelle Hopps, Markay Fallet, Shari Amass, Leslie Orphanet J Rare Dis Review We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden). East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors. The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%). Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]). Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4). The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN. Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%). Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1000-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-08 /pmc/articles/PMC6368811/ /pubmed/30736835 http://dx.doi.org/10.1186/s13023-019-1000-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Waddington-Cruz, Márcia
Schmidt, Hartmut
Botteman, Marc F.
Carter, John A.
Stewart, Michelle
Hopps, Markay
Fallet, Shari
Amass, Leslie
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title_full Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title_fullStr Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title_full_unstemmed Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title_short Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
title_sort epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368811/
https://www.ncbi.nlm.nih.gov/pubmed/30736835
http://dx.doi.org/10.1186/s13023-019-1000-1
work_keys_str_mv AT waddingtoncruzmarcia epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT schmidthartmut epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT bottemanmarcf epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT carterjohna epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT stewartmichelle epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT hoppsmarkay epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT falletshari epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries
AT amassleslie epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries